Pei-ran Zhou1, Xiao-jie Xu1, Zhen-lin Zhang2, Er-yuan Liao3, De-cai Chen4, Jian Liu5, Wen Wu6, Yan Jiang1, Ou Wang1, Wei-bo Xia1, Xiao-ping Xing1, Ling Xu7, Mei Li1. 1. Department of Endocrinology, Key Laboratory of Endocrinology of Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China. 2. Metabolic Bone Disease & Genetics Research Unit, Department of Osteoporosis & Bone Diseases, Shanghai Sixth People's Hospital Affiliated with Shanghai Jiao Tong University, Shanghai, China. 3. Institute of Endocrinology & Metabolism, Second Xiangya Hospital of Central South University, Changsha, Hunan, China. 4. Department of Endocrinology, Osteoporosis Education Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China. 5. Department of Orthopedics, Xijing Hospital, The Fourth Liberation Army University, Xi'an, Shaanxi, China. 6. Department of Endocrinology, Guangdong General Hospital, Guangzhou, Guangdong, China. 7. Department of Obstetrics & Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Abstract
AIM: To investigate the association between SOST gene polymorphisms and response to alendronate treatment. MATERIALS & METHODS: 639 Chinese postmenopausal women with osteoporosis or osteopenia received alendronate treatment. Polymorphisms of SOST were analyzed. Bone mineral density (BMD), serum ALP and β-CTX levels were measured. The correlation of SOST polymorphisms with changes of BMD and bone biomarkers after treatment was analyzed. RESULTS: rs1234612 and rs851054 polymorphisms were correlated to baseline lumbar spine BMD (p < 0.05). After 12 months of treatment rs1234612 and rs865429 polymorphisms were correlated to BMD changes at the lumbar spine (p < 0.05) or femoral neck (p < 0.05), respectively. CONCLUSION: The polymorphisms of SOST are genetic factors affecting bone health and response to alendronate in Chinese postmenopausal women.
AIM: To investigate the association between SOST gene polymorphisms and response to alendronate treatment. MATERIALS & METHODS: 639 Chinese postmenopausal women with osteoporosis or osteopenia received alendronate treatment. Polymorphisms of SOST were analyzed. Bone mineral density (BMD), serum ALP and β-CTX levels were measured. The correlation of SOST polymorphisms with changes of BMD and bone biomarkers after treatment was analyzed. RESULTS:rs1234612 and rs851054 polymorphisms were correlated to baseline lumbar spine BMD (p < 0.05). After 12 months of treatment rs1234612 and rs865429 polymorphisms were correlated to BMD changes at the lumbar spine (p < 0.05) or femoral neck (p < 0.05), respectively. CONCLUSION: The polymorphisms of SOST are genetic factors affecting bone health and response to alendronate in Chinese postmenopausal women.
Entities:
Keywords:
SOST gene; osteoporosis; polymorphisms; response to alendronate
Authors: C A D Lima; N R Javorski; A P O Souza; A D Barbosa; A P M C Valença; S Crovella; P R E Souza; J De Azevedo Silva; P Sandrin-Garcia Journal: Inflammopharmacology Date: 2017-02-21 Impact factor: 4.473
Authors: Alina Deniza Ciubean; Rodica Ana Ungur; Laszlo Irsay; Viorela Mihaela Ciortea; Ileana Monica Borda; Gabriela Bombonica Dogaru; Adrian Pavel Trifa; Stefan Cristian Vesa; Anca Dana Buzoianu Journal: PLoS One Date: 2019-11-27 Impact factor: 3.240